# A Study of Zoledronic Acid in the Prevention of Cancer Therapy-induced Bone Loss

> **NCT00333229** · PHASE4 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 11 (actual)

## Conditions studied

- Primary Hormone Receptor Negative Breast Cancer in Premenopausal Women

## Interventions

- **DRUG:** Zoledronic Acid
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00333229
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-03
- **Primary completion:** 2013-12
- **Final completion:** 2013-12
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** Due to rare patient population, planned number of patients could not be recruited in a reasonable timeframe. Recruitment was stopped prematurely.
- **Last updated:** 2014-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00333229

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00333229, "A Study of Zoledronic Acid in the Prevention of Cancer Therapy-induced Bone Loss". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT00333229. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*